These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29199173)

  • 21. Persistent reflux symptoms in the proton pump inhibitor era: the changing face of gastroesophageal reflux disease.
    Dellon ES; Shaheen NJ
    Gastroenterology; 2010 Jul; 139(1):7-13.e3. PubMed ID: 20493864
    [No Abstract]   [Full Text] [Related]  

  • 22. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
    Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Insufficient symptom control under long-term treatment with PPI in GERD - fact or fiction?].
    Labenz J; Labenz G; Stephan D; Willeke F;
    MMW Fortschr Med; 2016 May; 158 Suppl 4():7-11. PubMed ID: 27221555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between type 2 diabetes mellitus and failure to proton pump inhibitor treatment in gastroesophageal reflux disease.
    Hershcovici T; Jha LK; Gadam R; Cui H; Gerson L; Thomson S; Fass R
    J Clin Gastroenterol; 2012 Sep; 46(8):662-8. PubMed ID: 22858518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silent acid reflux and asthma control.
    Asano K; Suzuki H
    N Engl J Med; 2009 Apr; 360(15):1551-3. PubMed ID: 19357411
    [No Abstract]   [Full Text] [Related]  

  • 28. Management of gastro-oesophageal reflux disease symptoms that do not respond to proton pump inhibitors.
    Woodland P; Sifrim D
    Curr Opin Gastroenterol; 2013 Jul; 29(4):431-6. PubMed ID: 23549342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastroesophageal reflux disease: endoscopy, duration of treatment, and choice of PPI.
    Greenspan NR
    Med Health R I; 2011 Apr; 94(4):92-4. PubMed ID: 21667598
    [No Abstract]   [Full Text] [Related]  

  • 30. [Inadequate response to proton pump inhibitor therapy: causes and patient management tactics].
    Evsyutina YV; Trukhmanov AS
    Ter Arkh; 2015; 87(2):85-89. PubMed ID: 25864356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Gastroesophageal reflux disease--diagnosis and management].
    Wojtuń S; Gil J; Jałocha Ł; Błaszak A; Wojtkowiak M
    Pol Merkur Lekarski; 2009 May; 26(155):512-6. PubMed ID: 19606713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evidence and uncertainties on the clinical use of proton pump inhibitors].
    de Prados CM
    Gastroenterol Hepatol; 2010 May; 33 Suppl 1():5-10. PubMed ID: 20728783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with refractory reflux symptoms: What do they have and how should they be managed?
    Kahrilas PJ; Keefer L; Pandolfino JE
    Neurogastroenterol Motil; 2015 Sep; 27(9):1195-201. PubMed ID: 26303047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines.
    Haag S; Andrews JM; Katelaris PH; Gapasin J; Galmiche JP; Hunt R; Layer P; Malfertheiner P; Holtmann G
    Digestion; 2009; 80(4):226-34. PubMed ID: 19844107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proton pump inhibitor use in infants: FDA reviewer experience.
    Chen IL; Gao WY; Johnson AP; Niak A; Troiani J; Korvick J; Snow N; Estes K; Taylor A; Griebel D
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):8-14. PubMed ID: 21946832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refractory gastrooesophageal reflux disease.
    Bredenoord AJ; Smout AJ
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):217-23. PubMed ID: 18301303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On-demand requirements of patients with endoscopy-negative gastro-oesophageal reflux disease: H2-blocker vs. proton pump inhibitor.
    Juul-Hansen P; Rydning A
    Aliment Pharmacol Ther; 2009 Jan; 29(2):207-12. PubMed ID: 19006541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
    Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
    Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.